Shares of Veradermics Inc fell 4.8% to $97.90 midday on Tuesday, extending losses from the prior close of $102.82, as insider selling and a broader market pullback weighed on sentiment. The stock touched an intraday low of $93.81, according to trading data.
The decline followed the sale of nearly 1 million shares by executives and affiliated entities over the past week, including 67,500 shares by CEO Reid Alexander Waldman on August 17 under a prearranged 10b5-1 plan. Director John W. Childs-linked entities sold 100,000 shares on August 12, while Montanova Capital LLC, an affiliate of a director, disposed of 750,000 shares on August 19, reducing its position by 62%.
Veradermics also reported a net loss of $23.5 million for the second quarter of 2026, widening from a $15.6 million loss in the same period a year earlier. The company registered an additional 16.77 million shares for potential sale in early August, raising concerns over near-term supply.
The broader market contributed to the pressure, with the S&P 500 down 0.18% and the Nasdaq Composite falling 0.42%. Analysts at Citi and Jefferies maintain positive outlooks with price targets above current levels, though these views have not offset the immediate selling pressure.
